As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...
It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback